CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures.
A pan-cancer comparative analysis of the cancer genome atlas transcriptomic TIL-immune signatures.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
通过基础科学研究和癌症基因组图谱(TCGA)数据分析来理解肿瘤微环境的努力,已促成从TIL(肿瘤浸润淋巴细胞)中创建独特的免疫转录组特征。然而,尚无泛癌分析以总生存期(OS)或无进展间期(PFI)为终点来比较这些特征的预后性能。我们汇编了一个包含146个TIL免疫特征的文库,并评估了基因特征评分与33种肿瘤类型中9,961份可用TCGA样本的OS和PFI的相关性。Zhang CD8 TCS在泛癌范围内预测OS和PFI方面表现出更高的准确性;然而,在不同癌症类型和生殖细胞来源之间观察到变异性。聚类分析汇总了一组六个特征(Oh.Cd8.MAIT、Grog.8KLRB1、Oh.TIL_CD4.GZMK、Grog.CD4.TCF7、Oh.CD8.RPL、Grog.CD4.RPL32),其与OS和PFI的关联可能在多种肿瘤中保守。
Efforts to understand the tumor microenvironment through basic science research and the cancer genome atlas (TCGA) data analysis have led to the creation of unique immune transcriptomic signatures from tumor-infiltrating lymphocytes (TIL).
However, no pan-cancer analysis has been conducted to compare the prognostic performance of these signatures using overall survival (OS) or progression-free interval (PFI) as endpoints.
We compiled a library of 146 TIL-immune signatures and evaluated gene signature score correlation with OS and PFI for 9,961 available TCGA samples across 33 tumor types. Zhang CD8 TCS demonstrated higher accuracy in prognosticating both OS and PFI across the pan-cancer landscape; however, variability was seen across cancer types and germ cell origin.
Cluster analysis compiled a group of six signatures (Oh. Cd8. MAIT, Grog. 8KLRB1, Oh. TIL_CD4. GZMK, Grog. CD4. TCF7, Oh. CD8. RPL, Grog. CD4. RPL32) whose association with OS and PFI could potentially be conserved across multiple neoplasms.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。